Coloretti, I.; Berlot, G.; Busani, S.; De Rosa, F.G.; Donati, A.; Forfori, F.; Grasselli, G.; Mirabella, L.; Tascini, C.; Viale, P.;
et al. Rationale for Polyclonal Intravenous Immunoglobulin Adjunctive Therapy in COVID-19 Patients: Report of a Structured Multidisciplinary Consensus. J. Clin. Med. 2021, 10, 3500.
https://doi.org/10.3390/jcm10163500
AMA Style
Coloretti I, Berlot G, Busani S, De Rosa FG, Donati A, Forfori F, Grasselli G, Mirabella L, Tascini C, Viale P,
et al. Rationale for Polyclonal Intravenous Immunoglobulin Adjunctive Therapy in COVID-19 Patients: Report of a Structured Multidisciplinary Consensus. Journal of Clinical Medicine. 2021; 10(16):3500.
https://doi.org/10.3390/jcm10163500
Chicago/Turabian Style
Coloretti, Irene, Giorgio Berlot, Stefano Busani, Francesco Giuseppe De Rosa, Abele Donati, Francesco Forfori, Giacomo Grasselli, Lucia Mirabella, Carlo Tascini, Pierluigi Viale,
and et al. 2021. "Rationale for Polyclonal Intravenous Immunoglobulin Adjunctive Therapy in COVID-19 Patients: Report of a Structured Multidisciplinary Consensus" Journal of Clinical Medicine 10, no. 16: 3500.
https://doi.org/10.3390/jcm10163500
APA Style
Coloretti, I., Berlot, G., Busani, S., De Rosa, F. G., Donati, A., Forfori, F., Grasselli, G., Mirabella, L., Tascini, C., Viale, P., & Girardis, M.
(2021). Rationale for Polyclonal Intravenous Immunoglobulin Adjunctive Therapy in COVID-19 Patients: Report of a Structured Multidisciplinary Consensus. Journal of Clinical Medicine, 10(16), 3500.
https://doi.org/10.3390/jcm10163500
